Growing up with Idiopathic Pulmonary Arterial Hypertension: An Arduous Journey

Tanguy Dutilleux1, Nesrine Farhat2, Ruth Heying3

  • 1Department of Pediatric Cardiology, University Hospital Aachen, 52074 Aachen, Germany.

Pediatric Reports
|May 23, 2023
PubMed

Insights

Idiopathic pulmonary arterial hypertension (IPAH) is a rare, severe childhood disease. Early treatment stabilized but did not decrease pulmonary artery pressure, highlighting the need for novel therapies to improve quality of life.

Area of Science:

  • Pediatric Cardiology
  • Pulmonology
  • Rare Diseases

Background:

  • Idiopathic pulmonary arterial hypertension (IPAH) is a severe, uncommon condition affecting children.
  • Clinical presentation includes non-specific symptoms like exercise intolerance and fatigue.

Observation:

  • A 7-year-old boy with suspected pulmonary hypertension (PH) was diagnosed with IPAH.
  • Vasoreactive testing was negative, leading to treatment with sildenafil and bosentan.
  • Initial treatment stabilized pulmonary artery pressure for 5 years but did not improve quality of life.

Findings:

  • The patient experienced disease progression with increased pulmonary artery pressure and supra-systemic levels.
  • This deterioration necessitated enrollment in an ongoing clinical trial.

Implications:

  • IPAH significantly reduces quality of life in children and carries a high mortality/morbidity burden.
  • Current treatments offer limited long-term efficacy, emphasizing the need for advanced therapeutic strategies.
  • Further research into novel treatments for pediatric IPAH is crucial for improving patient outcomes and quality of life.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
240
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
274
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
215
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
226
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
200
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
376